US Pharma MarketingMerck, Gilead score in effort to develop the first weekly HIV pill
Merck, Gilead score in effort to develop the first weekly HIV pill is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
A combination of Merck’s islatravir and Gilead’s lenacapavir has succeeded in two phase 3 trials and is in line to become the first long-acting oral HIV treatment that can be taken weekly.
Source: FiercePharma